+

WO2005016360A1 - Preparations topiques au lactate d'ammonium - Google Patents

Preparations topiques au lactate d'ammonium Download PDF

Info

Publication number
WO2005016360A1
WO2005016360A1 PCT/IL2004/000541 IL2004000541W WO2005016360A1 WO 2005016360 A1 WO2005016360 A1 WO 2005016360A1 IL 2004000541 W IL2004000541 W IL 2004000541W WO 2005016360 A1 WO2005016360 A1 WO 2005016360A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
composition
cosmetic
weight percentages
cosmeceutical
Prior art date
Application number
PCT/IL2004/000541
Other languages
English (en)
Inventor
Moshe Arkin
Nir Avram
Olga Buriakovsky
Amira Zeevi
Benjamin Schneider
Stephen Cherkez
Stella Nivy
Original Assignee
Agis Industries (1983) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/850,462 external-priority patent/US20050036953A1/en
Priority claimed from US10/850,435 external-priority patent/US20050042182A1/en
Priority claimed from US10/850,461 external-priority patent/US20050037040A1/en
Application filed by Agis Industries (1983) Ltd. filed Critical Agis Industries (1983) Ltd.
Publication of WO2005016360A1 publication Critical patent/WO2005016360A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to pharmaceutical, cosmetic and cosmeceutic compositions for topical application, and their use in the treatment of medical, cosmetic and cosmeceutical conditions such as dry skin and/or scalp.
  • Dry skin is a common condition associated with a plurality of disorders and frequently requires therapeutic intervention.
  • Dermatologists often call dry skin in later life "xerosis" or "ichthyosis".
  • Xerosis is a term used to describe abnormal skin dryness.
  • Ichthyosis is a term used to describe a group of cutaneous disorders characterized by increased or aberrant keratinisation, and resulting in non-inflammatory scaling of the skin.
  • ichthyosis There are at least twenty varieties of ichthyosis, including inherited and acquired forms. Further details regarding xerosis and ichthyosis can be found in "Atlas of Clinical Dermatology” by Anthony du Nivier, 3rd edition (July 17, 2002) Publisher: Churchill Livingstone, which is incorporated herein by reference. Dry skin often leads to dermatitis, a condition in which the skin becomes red and itchy, and which is typically characterized by a crazy-paving appearance on the lower legs (eczema craquele) or round patches scattered over the trunk and limbs (a dry form of nummular dermatitis).
  • dermatitis a condition in which the skin becomes red and itchy, and which is typically characterized by a crazy-paving appearance on the lower legs (eczema craquele) or round patches scattered over the trunk and limbs (a dry form of nummular dermatitis).
  • the dry skin is just itchy, without much of a rash. Dry skin results from, or is aggravated by, low humidity, sunlight, abrasive clothing and/or a repeated use of soaps, detergents or other lipid solvents, and is further strongly influenced by factors such as age, race, genetics, climate and lifestyle.
  • moisturizer to soften
  • humectants which are introduced into the stratum corneum to increase its water holding capacity
  • occlusives which provide a layer of oil on the surface of the skin to slow water loss and thus increase the moisture content of the stratum corneum.
  • Some moisturizers contain both occlusives and humectants.
  • “Emollients” is a general term used to describe substances that cover the surface of the stratum corneum so as to prevent moisture loss, thus resulting in the closure of microcracks and fissures and restoration of the natural epidermal barrier. (Marie Loden, Clinics in Dermatology, 21, 145-157, 2003).
  • hydrating agent are used interchangeably.
  • the final form of a topical composition plays an important role in its efficacy and its usage convenience, particularly in cases where the composition is used to treat a skin condition associated with dry skin and/or scalp.
  • the challenge in topically applying a composition is to achieve percutaneous penetration of the active agent to the site of treatment, in many cases the epidermis.
  • it is important that the composition should have desirable characteristics.
  • application should be easy, smooth and should result in no irritation, discomfort or inconvenience.
  • the composition should not leave a residue on the surface of the skin.
  • Topical compositions in forms such as gels, ointments, lotions, creams, pads and pastes are often very viscous, requiring substantial rubbing to achieve penetration of the active agent to the affected skin layer, an act which often results in discomfort and further irritation.
  • Non-viscous creams and lotions require quick and dexterous application as they are inclined to flow off the site of treatment before penetration of the active ingredient is achieved.
  • foams are well suited for the topical application of compositions.
  • Foam compositions are typically formulated in a single or multiple phase liquid form and housed in a suitable container, optionally together with a propellant which facilitates the expulsion of the composition from the container, thus trai-Lsfo ⁇ ning it into a foam upon application.
  • foam forming techniques include, for example the "Bag-in-a-can" formulation technique.
  • Compositions thus formulated typically contain a low-boiling hydrocarbon, e.g., isopropane. Application and agitation of such a composition at the body temperature cause the isopropane to vaporize and generate the foam, in a manner similar to a pressurized aerosol foaming system.
  • a foam composition has physical characteristics which are dependent, at least in part, upon the choice and relative amounts of components such as solvents, propellants and surfactants, which may be present in the composition.
  • the combination of these components determines the stability of the foam, which may retain its foam-like structure upon application or, alternatively, may be "a slow- breaking foam” or "a quick-breaking foam", whereby this terminology relates to the behavior of the foam towards shearing action as is sustained when the foam is rubbed into or spread over a surface onto which it has been dispensed.
  • Many of the physical characteristics of foam compositions render it highly beneficial and advantageous over other forms.
  • One such exemplary characteristic is the semi-solid to solid nature of the foam matrix, which allows the composition to be applied with the hand in any orientation without the risk of run off.
  • Another beneficial characteristic of foams is their convenient application to large areas of the body surface.
  • foams can be water-based or hydroalcoholic, typically they are formulated with high alcohol content which, upon application to the skin of a user, quickly evaporates, driving the active ingredient through the upper skin layers to the site of treatment.
  • Ammonium lactate which is the ammonium salt of lactic acid (also known as alpha-hydroxy propanoic acid), is a well-known emollient.
  • Presently available commercial preparations that contain ammonium lactate include, for example, creams or lotions, which comprise up to 12 % ammonium lactate (e.g., Lac-Hydrin 12 % and Lac-Hydrin 5 %, marketed by Westwood Squibb, a division of Bristol-Myers Squibb).
  • compositions containing these active ingredients are preferably formulated as lotions, creams, ointments or gels, which, as is described hereinabove, are disadvantageous in treating dry skin conditions.
  • these patents are completely silent with respect to foamable compositions that include ⁇ -hydroxy acids, ⁇ -keto acids and/or derivatives thereof.
  • 5,393,526 discloses a cosmetic facial foundation composition, which includes, as active ingredients, alpha-hydroxy carboxylate compound such as glycolic acid, lactic acid and/or their salts, in a concentration of from about 0.01 % to about 10 % by weight, and a rosmarinic acid or a salt thereof, in a concentration of from about 0.05 % to about 5 % by weight.
  • alpha-hydroxy carboxylate compound such as glycolic acid, lactic acid and/or their salts
  • a rosmarinic acid or a salt thereof in a concentration of from about 0.05 % to about 5 % by weight.
  • compositions are preferably formulated as liquids, gels, creams, lotions and powders
  • this patent is completely silent with respect to foamable compositions that include alpha-hydroxy acids and/or derivatives thereof.
  • U.S. Patent No. 5,482,710 discloses a cosmetic composition for the treatment of pimples, blemishes and redness.
  • the disclosed composition contains a keratolytic agent such as alpha-hydroxy carboxylic acid and/or salts thereof, in a concentration of from about 0.1 % to about 10 % by weight, and preferably from about 0.2 % to about 1 % by weight, and an anti-irritancy agent, which comprises a combination of water soluble anti-irritant and a water insoluble anti-irritant, in a concentration of from about 0.0001 % to about 5 % by weight, preferably from about
  • compositions for treating external symptoms such as pimples, blemishes and redness and is therefore not directed to compositions that are aimed at being efficiently absorbed in the skin.
  • this patent is directed to compositions that include a combination of the active ingredients described above, where the concentration of the keratolytic agent is relatively low and therefore fails to teach a composition that includes ammonium lactate as an active ingredient for treating dry skin and/or scalp conditions and associated disorders.
  • 5,679,324 discloses quick-breaking foamable fragrance compositions, which comprise a surfactant, a propellant, a fragrance and a thickener. These compositions, according to the teachings of this patent, may optionally further include skin moisturizers such as lactic acid and salts thereof. As this patent is directed to fragrance compositions, it fails to teach compositions for treating dry skin conditions, in which ammonium lactate is present in an effective amount for treating these conditions.
  • U.S. Patent No. 6,086,903 discloses a personal treatment composition that comprises an enduring perfume composition.
  • ammomum lactate may optionally be added to the composition as a moisturizer, in a concentration of, as arbitrarily stated, between 0.1 % and 20 %, preferably, as stated, in a low concentration of between 2 % and 5 %.
  • this reference is directed to personal treatment compositions in which ammonium lactate is an optional adjuvant and fails to teach compositions for treating dry skin conditions, in which ammonium lactate is present in an effective amount for treating these conditions.
  • U.S. Patent Application No. 20020151446 discloses a foaming cleanser composition that comprises a mild surfactant system, a moisturizer system and a solvent system.
  • ammonium lactate can be one of the usable surfactants, and one of the suitable moisturizers. While this patent is directed to cleansing and conditioning of hair and skin, it fails to teach compositions for treating diseased or compromised skin. Thus, the prior art fails to teach foamable compositions for treating dry skin and scalp conditions and associated disorders, which include ammomum lactate or any other alpha-hydroxy acid or salts thereof in an effective amount.
  • ammonium lactate compositions are highly disadvantageous, particularly in treating dry skin and scalp conditions, , and further as foamable compositions are highly advantageous in this respect, there is a widely recognized need for, and it would be highly advantageous to have, foamable compositions of ammonium lactate or analogs thereof for treating dry skin and scalp conditions and related disorders, as well as other medical, cosmetic and cosmeceutical conditions, devoid of the above limitations.
  • foamable compositions that comprise an alpha-hydroxy carboxylic acid and/or a salt thereof, such as ammonium lactate, in a relatively high concentration, can serve as efficient pharmaceutical, cosmetic and cosmeceutical compositions for the treatment of various dermatological disorders (e.g., dry skin and/or scalp).
  • a foamable pharmaceutical, cosmetic or cosmeceutical composition for topical application which is identified for use in the treatment of a medical, cosmetic and/or cosmeceutical condition associated with dry skin and or scalp.
  • composition of the present invention comprises one or more alpha-hydroxy carboxylic acids and/or salts thereof, one or more propellant(s) and a pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • alpha-hydroxy carboxylic acids and/or the salts thereof according to the present invention preferably has a general formula:
  • the alpha-hydroxy carboxylic acids and/or the salts thereof comprise lactic acid and/or a salt thereof, e.g., ammonium lactate.
  • a foamable pharmaceutical, cosmetic or cosmeceutical composition for topical application as described hereinabove which comprises ammonium lactate, one or more propellant(s) and a pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • each of the foamable pharmaceutical, cosmetic or cosmeceutical compositions of the present invention is packaged in a packaging material and identified in print, in or on the packaging material, for use in the treatment of a medical, cosmetic and/or cosmeceutical condition associated with dry skin and/or scalp, such as, but not limited to, xerosis, ichthyosis, keratosis, keratoderma, pruritus, acne, dermatitis, neuro-dermatitis, dermatitis herpetiformis, actinic keratosis, hyper keratosis, inflamed keratosis, eczema, atopic eczema, melanoma, psoriasis, rosacea, urticaria, seborrheic dermatitis, skin cancer, and xeroderma pigmentosum.
  • a medical, cosmetic and/or cosmeceutical condition associated with dry skin and/or scalp such as,
  • the concentration of the ammonium lactate or of the alpha-hydroxy carboxylic acid and/or the salt thereof is greater than 5 weight percentages of the total weight of the composition. More preferably it is greater than 10 weight percentages. According to still further features in the described preferred embodiments the concentration of the ammonium lactate or of the alpha-hydroxy carboxylic acid and/or the salt thereof ranges between about 5.1 weight percentages and about 30 weight percentages of the composition. More preferably, it ranges between about 8 weight percentages and about 20 weight percentages of the composition.
  • the concentration of the propellant(s) preferably ranges between about 0.5 weight percentage and about 60 weight percentages, more preferably between about 10 weight percentages and about 20 weight percentages.
  • each of the compositions of the present invention further comprises one or more additional active ingredient(s) selected from the group consisting of an antibiotic agent, an antimicrobial agent, an anti-acne agent, an antibacterial agent, an antifungal agent, an antiviral agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoal agent, an anti- oxidant, a chemotherapeutic agent, an antidepressant, an antihistamine, a vitamin, a hormone and an antidandruff agent.
  • additional active ingredient(s) selected from the group consisting of an antibiotic agent, an antimicrobial agent, an anti-acne agent, an antibacterial agent, an antifungal agent, an antiviral agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoal agent, an anti- oxidant,
  • each of the compositions of the present invention further comprises one or more ingredient(s) selected from the group consisting of a humectant, a deodorant agent, an antiperspirant, a sun screening agent, a sunless tanning agent, a hair conditioning agent, a pH adjusting agent, a chelating agent, a preservative, an emulsifier, an occlusive agent, an emollient, a thickener, a solubilizing agent, a penetration enhancer, an anti-irritant, a colorant and a surfactant.
  • the anti-irritant is either a water-soluble anti-irritant or a water-insoluble anti-irritant.
  • the pharmaceutical, cosmetic or cosmeceutical compositions of the present invention preferably have a pH value that ranges between about 4.0 and about 7.0, more preferably between about 5.0 and about 6.0.
  • the pharmaceutical, cosmetic or cosmeceutical compositions of the present invention are preferably devoid of an enduring perfume composition.
  • processes of preparing the pharmaceutical, cosmetic or cosmeceutical compositions of the present invention comprises admixing the ammomum lactate or the alpha-hydroxy carboxylic acid and/or the salt thereof, described hereinabove, the propellant(s) and a pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • the processes further comprise admixing the active ingredient or any other ingredient with the ammonium lactate or the alpha-hydroxy carboxylic acid and/or the salt thereof, the propellant and the carrier.
  • the methods comprise topically applying onto one or more biological surface(s) of a subject in need thereof, a pharmaceutically, cosmetically or cosmeceutically effective amount of any one of the compositions described hereinabove.
  • the one or more biological surface(s) is selected from the group consisting of a lateral aspect of a forearm, a lateral aspect of a leg, an elbow, a pal-m, a foot, a backhand, a back and a scalp.
  • the present invention successfully addresses the shortcomings of the presently known configurations by providing foamable compositions containing ammonium lactate or any other alpha-hydroxy carboxylic acid and/or a salt thereof, which are highly efficient and convenient to use, and methods of treating conditions associated with dry skin and/or scalp, as well as other medical, cosmetic and cosmeceutical conditions, utilizing same..
  • all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control.
  • the materials, methods, and examples are illustrative only and not intended to be limiting.
  • FIG. 1 is a bar graph presenting the results obtained in a comparative test of the therapeutic effects of a foamable composition according to the present invention and of a control commercially available ammonium lactate cream composition.
  • compositions for topical application which can be efficiently used in the treatment of various medical, cosmetic and/or cosmeceutical conditions.
  • the present invention is of (i) compositions for topical application, which contain, as an active ingredient, an alpha-hydroxy carboxylic acid and/or a salt thereof (e.g., ammonium lactate); (ii) processes of preparing these compositions; and (iii) their use in treating medical, cosmetic and/or cosmeceutical conditions such as, but not limited to, xerosis, ichthyosis, keratosis, keratoderma, pruritus, acne, dermatitis, neuro-dermatitis, dermatitis herpetiformis, actinic keratosis, hyper keratosis, inflamed keratosis, eczema, atopic eczema, melanoma,
  • hydrating efficacy and hence, the therapeutic or cosmetic performance, as well as the usage convenience of hydrating agents and any other agents for topical application depend, inter alia, on the final form of the composition in which these agents are formulated.
  • foam formulations are well suited for the topical application of compositions.
  • the presently known preparations that include a hydrating agent such as ammonium lactate as the active ingredient are typically formulated as creams, lotions, gels, ointment and the like, and therefore their efficacy and usage convenience are limited.
  • foam compositions which include ammonium lactate as an optional ingredient are known, these compositions are not aimed at treating dry skin or scalp conditions and therefore do not include ammonium lactate in a substantial concentration, such that it may serve as the main active hydrating agent.
  • compositions that comprises ammonium lactate, preferably in a relatively high concentration, which is formulated as a foam are highly efficient in the treatment of dry skin and/or scalp and is further characterized by improved absorption, after feel and comfort, as compared with the presently known formulations, and is devoid of stickiness and other adverse effects that accompany the use of the presently known formulations.
  • ammonium lactate preferably in a relatively high concentration
  • a foamable pharmaceutical, cosmetic or cosmeceutical composition for topical application which is identified for use in the treatment of a medical, cosmetic and/or cosmeceutical condition associated with dry ski and/or scalp.
  • the composition comprises ammonium lactate, one or more propellant(s) and a pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • topical application describes application onto a biological surface, e.g., skin or scalp.
  • a composition for topical application describes a composition that is applied to a subject by direct laying or spreading on the skin, scalp or any other biological surface of the subject.
  • the topical application is preferably performed onto a dry skin area.
  • the dry skin area can be, for example, the lateral aspect of a forearm, the lateral aspect of a leg, an elbow, a palm, a foot, a backhand, a back and/or a scalp.
  • comprising means that other steps and ingredients which do not affect the end results can be added. This term encompasses the terms "consisting of and “consisting essentially of.
  • the phrase "consisting essentially of means that the composition may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
  • active ingredient means an ingredient that exerts a pharmaceutical, cosmetic or cosmeceutical activity.
  • ammonium lactate and other alpha-hydroxy acids are known hydrating agents and thus the composition of the present invention is preferably directed to treat or prevent dry skin or scalp
  • the phrase "active ingredient” whenever used herein in the context of ammonium lactate and other alpha-hydroxy acids refers to an ingredient that exerts hydration activity, namely, a hydrating agent.
  • ammonium lactate serves as the main active ingredient in the composition of the present invention, its concentration is relatively high, so as to efficiently serve as a hydrating agent.
  • the concentration of ammomum lactate in the composition of the present invention is preferably greater than 5 weight percentages, more preferably greater than 6 weight percentages, more preferably greater than 7 weight percentages, more preferably greater than 8 weight percentages, more preferably greater than 9 weight percentages, more preferably greater than 10 weight percentages, more preferably greater than 11 weight percentages, and more preferably it is about 12 weight percentages, 13 weight percentages or 14 weight percentages of the total weight of the composition.
  • the phrase "greater than” as used herein throughout with respect to a numerical indication encompasses any number (integral or fractional) that is greater than the indicated number.
  • the concentration of ammonium lactate in the composition of the present invention can further preferably be greater than 14 weight percentages and up to about 30 weight percentages.
  • the ammonium lactate concentration in the composition preferably ranges between, for example, 5.1 weight percentages and about 30 weight percentages, more preferably between about 8 and about 20 weight percentages, more preferably between about 8 and about 16 weight percentages, and even more preferably between about 10 and about 16 weight percentages, with a concentration that ranges between An ammonium lactate concentration that ranges between about 12 weight percentages and about 14 weight percentages is being the presently most preferred concentration.
  • weight percentages describes the weight percentages (of an ingredient) of the total weight of a composition containing same.
  • ammonium lactate is a preferable hydrating agent
  • other hydrating agents that belong to the well-known alpha-hydroxy acids family, can be used as active ingredients in the foamable compositions of the present invention.
  • Such hydrating agents which are used for treating dry skin are described, for example, in U.S. Patents Nos. 3,879,537, 3,920,835, 3,984,470, 3,988,470, 4,021,572, 4,105,783, 4,246,261, 4,363,815, 5,422,370, and 5,554,597.
  • composition for topical application, which is identified for use in the treatment of a medical, cosmetic and/or cosmeceutical condition associated with dry skin and/or scalp.
  • the composition comprises, as an active ingredient, one or more alpha-hydroxy carboxylic acid(s) and or salt(s) thereof, one or more propellants, and a pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • alpha-hydroxy carboxylic acid or the salt thereof according to the present invention can be generally described by the general formula:
  • X is hydrogen, alkyl, cycloalkyl, aryl, halide, or an ammonium ion, such that when X is an ammonium ion, O is negatively charged, or, alternatively, X is a C2-C10 alkyl that is attached to C 2 ; and Ra and Rb are each independently hydrogen, halide, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, or a salt thereof.
  • alkyl refers to a saturated aliphatic hydrocarbon including straight chain and branched chain groups.
  • the alkyl group has 1 to 20 carbon atoms.
  • the alkyl group may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms. More preferably, it is a medium size alkyl having 1 to 10 carbon atoms. Most preferably, it is a lower alkyl having 1 to 4 carbon atoms.
  • the alkyl group may be substituted or unsubstituted.
  • the substituent group can be, for example, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halide, carbonyl, thiocarbonyl, nitro and/or amino.
  • cycloalkyl refers to an all-carbon monocyclic or fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system.
  • cycloalkyl groups examples, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane.
  • a cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent group can be, for example, alkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halide, carbonyl, thiocarbonyl, nitro and/or amino.
  • aryl refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups having a completely conjugated pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or unsubstituted.
  • the substituent group can be, for example, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halide, carbonyl, thiocarbonyl, nitro and/or amino.
  • halide refers to a fluoride, chloride, bromide or iodide radical.
  • heteroaryl refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms, such as, for example, nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi-electron system.
  • heteroaryl groups include pyrrole, furane, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline and purine.
  • the heteroaryl group may be substituted or unsubstituted.
  • the substituent group can be, for example, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicychc, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halide, carbonyl, thiocarbonyl, nitro and/or amino.
  • heteroalicyclic refers to a monocyclic or fused ring group having in the ring(s) one or more atoms such as nitrogen, oxygen and sulfur. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system.
  • the heteroalicyclic may be substituted or unsubstituted.
  • the substituent group can be, for example, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halide, carbonyl, thiocarbonyl, nitro and/or amino.
  • hydroxy refers to an -OH group.
  • alkoxy refers to both an -O-alkyl and an -O-cycloalkyl group, as defined herein.
  • aryloxy refers to both an -O-aryl and an -O-heteroaryl group, as defined herein.
  • a "thiohydroxy” group refers to an -SH group.
  • a “thioalkoxy” group refers to both an -S-alkyl group, and an -S-cycloalkyl group, as defined herein.
  • a “thioaryloxy” group refers to both an -S-aryl and an -S-heteroaryl group, as defined herein.
  • the term "amine” or “amino” refers to an -NR'R” group where R' and R" are as defined herein.
  • the term “ammonium ion” refers to an -N + R'R"R"' group where R'" is as defined here for R', and R' and R" are as defined herein.
  • a "nitro” group refers to an -NO 2 group.
  • a “cyano” group refers to a -C ⁇ N group.
  • alkenyl refers to an alkyl group, as is defined hereinabove, which consists of at least two carbon atoms and at least one carbon-carbon double bond.
  • alkynyl refers to an alkyl group, as is defined hereinabove, which consists of at least two carbon atoms and at least one carbon-carbon triple bond.
  • the alpha-hydroxy carboxylic acid according to the present invention can be in a form of the free acid, such that X in the formula above is hydrogen, or a salt thereof, or, alternatively, the alpha-hydroxy carboxylic acid can be in a form of an ester, such that X in the formula above is alkyl, cycloalkyl or aryl, as these terms are defined hereinabove, or a salt thereof in some cases where the alkyl, cycloalkyl or aryl is substituted.
  • the alpha-hydroxy carboxylic acid can further be in a form of an acyl chloride, such that X in the formula above is halide, or in a form of a lactone, such that X is the formula above is an alkyl that is attached to C 2 , or a salt thereof, in some cases where the alkyl is substituted.
  • the alpha-hydroxy carboxylic acid can be in a form of an ammonium salt, such that X in the formula hereinabove is an ammonium ion.
  • an ammonium ion is a positively charged ion
  • O in the formula above is negatively charged in this case.
  • alpha-hydroxy carboxylic acid and salts thereof that are usable in the context of this aspect of the present invention include, without limitation, 2-hydroxyethanoic acid (glycolic acid); 2-hydroxypropanoic acid (lactic acid); 2-methyl 2-hydroxypropanoic acid (methyllactic acid); 2-hydroxybutanoic acid; 2-hydroxypentanoic acid; 2-hydroxyhexanoic acid; 2-hydroxyheptanoic acid; 2- hydroxyoctanoic acid; 2-hydroxynonanoic acid; 2-hydroxydecanoic acid; 2- hydroxyundecanoic acid; 2-hydroxydodecanoic acid (alph.-hydroxylauric acid); 2- hydroxytetradecanoic acid (alpha-hydroxymyristic acid); 2-hydroxyhexadecanoic acid (alpha-hydroxypalmitic acid); 2-hydroxyoctadecanoic acid (alpha-hydroxystearic acid); 2-hydroxyeicosanoic acid (alpha-hydroxyarachidontc acid); 2-phenyl 2-hydroxyethan
  • the concentration of the alpha-hydroxy carboxylic acid or the salt thereof in the composition according to this aspect of the present invention is greater than 5 weight percentages of the composition, preferably greater than 6 weight percentages, more preferably greater than 7 weight percentages, more preferably greater than 8 weight percentages, more preferably greater than 9 weight percentages, more preferably greater than 10 weight percentages, more preferably greater than 11 weight percentages, and most preferably is about 12 weight percentages, 13 weight percentages or 14 weight percentages.
  • the concentration of the alpha-hydroxy carboxylic acid or the salt thereof in the composition of the present invention can further preferably be greater than 14 weight percentages and up to 20 weight percentages.
  • the concentration of the ammonium salt of the organic acid in the composition preferably ranges between 5.1 weight percentages and about 20 weight percentages, more preferably between about 8 and about 16 weight percentages, more preferably between about 10 and about 16 weight percentages, whereby a concentration that ranges between about 12 and about 14 weight percentages is being the presently most preferred.
  • Each of the compositions of the present invention, described hereinabove further includes a pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • the term "pharmaceutically, cosmetically or cosmeceutically acceptable carrier” describes a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the applied active ingredient.
  • acceptable carriers that are usable in the context of the present invention include carrier materials that are well-known for use in the cosmetic and medical arts as bases for foams, aerosols and the like.
  • the compositions of the present invention are formulated in the form of a foam.
  • the foam is formed by the passage of a pressurized mixture of a concentrate and a propellant through a nozzle.
  • the propellant is in the form of a compressed gas, typically a liquefiable gas.
  • the mixture is preferably contained in a dispenser equipped with a dispensing head and valve, and pressurized with the propellant.
  • a dispenser equipped with a dispensing head and valve, and pressurized with the propellant.
  • the volatilization of the dispersed liquid droplets of propellant causes the dispensed concentrate to foam.
  • the dispensed product may range from a dense creamy foam to a light foam, dependent on desired aesthetics in the hand and when spread onto the substrate.
  • the concentration of the propellant in the composition preferably ranges between about 0.5 and about 60 weight percentages, more preferably between about 1 and about 20 weight percentages of the total composition.
  • propellant suitable for use in pharmaceutical, cosmetic or cosmeceutical compositions can be used herein, alone or in combination with other propellant.
  • suitable propellants include nitrous oxide, carbon dioxide, nitrogen, and hydrocarbon propellants such as propane, iso-butane, n-butane, isopentane, n-pentane, and dimethyl ether.
  • Preferred propellants are selected from, for example, propane, iso-butane, n-butane, isopentane, n-pentane, and mixtures thereof.
  • Chlorinated fluorocarbons such as 1,1-difluoro- or 1,1,1,2-tetrafluoroethane are also suitable but their use is being limited for environmental reasons. These propellants usually have a low boiling point and are in a gaseous form at room temperature in standard conditions.
  • the compositions of the present invention can optionally further comprise a variety of components that are suitable for rendering the compositions more cosmetically or aesthetically acceptable or to provide the compositions with additional usage benefits. Such conventional optional components are well known to those skilled in the art and are referred to herein as "ingredients".
  • these include any cosmetically acceptable ingredients such as those found in the CTFA International Cosmetic Ingredient Dictionary and Handbook, 8th edition, edited by Wenninger and Canterbery, (The Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, D.C., 2000).
  • Some non-limiting representative examples of these ingredients include humectants, deodorants, antiperspirants, sun screening agents, sunless tanning agents, hair conditioning agents, pH adjusting agents, chelating agents, preservatives, emulsifiers, occlusive agents, emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants, colorants and surfactants.
  • compositions of the present invention can comprise, in combination with ammonium lactate or any other alpha-hydroxy carboxylic acid or a salt thereof, one or more additional humectants or moisturizing agents.
  • additional humectants or moisturizing agents include, without limitation, guanidine, glycolic acid and glycolate salts (e.g.
  • aloe vera in any of its variety of forms (e.g., aloe vera gel), allantoin, urazole, polyhydroxy alcohols such as sorbitol, glycerol, hexanetriol, propylene glycol, butylene glycol, hexylene glycol and the like, polyethylene glycols, sugars and starches, sugar and starch derivatives (e.g., alkoxylated glucose), hyaluronic acid, lactamide monoethanolamine, acetamide monoethanolamine and any combination thereof.
  • the compositions of the present invention can further comprise a pH-adjusting agent.
  • Suitable pH adjusting agents include, for example, one or more adipic acids, glycines, citric acids, calcium hydroxides, magnesium aluminometasilicates, buffers or any combinations thereof.
  • compositions for topical application should preferably have a pH value of between 4.0 and 7.0, preferably between 5.0 and 6.0, most preferably about 5.5 or substantially 5.5, so as to avoid irritation.
  • a pH adjusting is typically added so as to bring the PH of the composition to the desired value.
  • the compositions of the present invention are therefore preferably formulated so as to have a pH value that ranges between about 4.0 and about 7.0, more preferably between bout 5.0 and about 6.0.
  • deodorant agents that are usable in the context of the present invention include, without limitation, quaternary ammonium compounds such as cetyl-trimethylammonium bromide, cetyl pyridinium chloride, benzethonium chloride, diisobutyl phenoxy ethoxy ethyl dimethyl benzyl ammonium chloride, sodium N-lauryl sarcosine, sodium N-palmlthyl sarcosine, lauroyl sarcosine, N- myristoyl glycine, potassium N-lauryl sarcosine, stearyl, trimethyl ammonium chloride, sodium aluminum chlorohydroxy lactate, tricetylmethyl ammonium chloride, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, diaminoalkyl amides such as L- lysine hexadecyl amide, heavy metal salts of citrate, salicylate,
  • deodorant agents include, without limitation, odor absorbing materials such as carbonate and bicarbonate salts, e.g. as the alkali metal carbonates and bicarbonates, ammonium and tefraalkylammonium carbonates and bicarbonates, especially the sodium and potassium salts, or any combination of the above.
  • Antiperspirant agents can be incorporated in the compositions of the present invention either in a solubilized or a particulate form and include, for example, aluminum or zirconium astringent salts or complexes.
  • sun screening agents include, without limitation, p-aminobenzoic acid, salts and derivatives thereof (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid); anthranilates (i.e., o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters); cinnamic acid derivatives (menthyl and benzyl esters, a-phenyl cinnamonitrile; butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone
  • sunless tanning agents usable in context of the present invention include, without limitation, dihydroxyacetone, glyceraldehyde, indoles and their derivatives.
  • the sunless tanning agents can be used in combination with the sunscreen agents.
  • Suitable hair conditioning agents that can be used in the context of the present invention include, for example, one or more collagens, cationic surfactants, modified silicones, proteins, keratins, dimethicone polyols, quaternary ammomum compounds, halogenated quaternary ammonium compounds, alkoxylated carboxylic acids, alkoxylated alcohols, alkoxylated amides, sorbitan derivatives, esters, polymeric ethers, glyceryl esters, or any combinations thereof.
  • the chelating agents are optionally added to the compositions of the present invention so as to enhance the preservative or preservative system.
  • Preferred chelating agents are mild agents, such as, for example, ethylenediaminetetraacetic acid (EDTA), EDTA derivatives, or any combination thereof.
  • Suitable preservatives for use in the compositions of the present composition include, without limitation, one or more alkanols, disodium EDTA (ethylenediamine tetraacetate), EDTA salts, EDTA fatty acid conjugates, isothiazolinone, parabens such as methylparaben and propylparaben, propylene glycols, sorbates, urea derivatives such as diazolindinyl urea, or any combinations thereof.
  • Suitable emulsifiers that can be used in the context of the present invention include, for example, one or more sorbitans, alkoxylated fatty alcohols, alkylpolyglycosides, soaps, alkyl sulfates, monoalkyl and dialkyl phosphates, alkyl sulp onates, acyl isothionates, or any combinations thereof.
  • Suitable occlusive agents that can be used in the context of the present invention include, for example, petrolatum, mineral oil, beeswax, silicone oil, lanolin and oil-soluble lanolin derivatives, saturated and unsaturated fatty alcohols such as behenyl alcohol, hydrocarbons such as squalane, and various animal and vegetable oils such as almond oil, peanut oil, wheat germ oil, linseed oil, jojoba oil, oil of apricot pits, walnuts, palm nuts, pistachio nuts, sesame seeds, rapeseed, cade oil, corn oil, peach pit oil, poppyseed oil, pine oil, castor oil, soybean oil, avocado oil, safflower oil, coconut oil, hazelnut oil, olive oil, grape seed oil and sunflower seed oil.
  • petrolatum mineral oil
  • beeswax silicone oil
  • lanolin and oil-soluble lanolin derivatives saturated and unsaturated fatty alcohols such as behenyl alcohol
  • hydrocarbons such
  • Suitable emollients other than ammonium lactate or the alpha-hydroxy carboxylic acid or the salt thereof, that can be used in the context of the present invention include, for example, dodecane, squalane, cholesterol, isohexadecane, isononyl isononanoate, PPG Ethers, petrolatum, lanolin, safflower oil, castor oil, coconut oil, cottonseed oil, palm kernel oil, palm oil, peanut oil, soybean oil, polyol carboxylic acid esters, derivatives thereof and mixtures thereof.
  • Suitable thickeners that can be used in the context of the present invention include, for example, non-ionic water-soluble polymers such as hydroxy ethylcellulose (commercially available under the Trademark Natrosol R TM 250 or 350), cationic water-soluble polymers such as Polyquat 37 (commercially available under the Trademark Synthalen R TM CN), fatty alcohols, fatty acids and their alkali salts and mixtures thereof.
  • non-ionic water-soluble polymers such as hydroxy ethylcellulose (commercially available under the Trademark Natrosol R TM 250 or 350), cationic water-soluble polymers such as Polyquat 37 (commercially available under the Trademark Synthalen R TM CN), fatty alcohols, fatty acids and their alkali salts and mixtures thereof.
  • solubilizing agents that are usable in this context of the present invention include, without limitation, complex-forming solubilizers such as citric acid, ethylenediamine-tetraacetate, sodium meta-phosphate, succinic acid, urea, cyclodextrin, polyvinylpyrrolidone, diethylammonium-ortho-benzoate, and micelle-fo-rming solubilizers such as TWEENS and spans, e.g., TWEEN 80.
  • complex-forming solubilizers such as citric acid, ethylenediamine-tetraacetate, sodium meta-phosphate, succinic acid, urea, cyclodextrin, polyvinylpyrrolidone, diethylammonium-ortho-benzoate, and micelle-fo-rming solubilizers such as TWEENS and spans, e.g., TWEEN 80.
  • solubilizers that are usable for the compositions of the present invention are, for example, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene n-alkyl ethers, n- alkyl amine n-oxides, poloxamers, organic solvents, phospholipids and cyclodextrines.
  • Suitable penetration enhancers usable in context of the present invention include, but are not limited to, dimethylsulfoxide (DMSO), dimethyl formamide (DMF), allantoin, urazole, N,N-dimethylacetamide (DMA), decylmethylsulfoxide (Cio MSO), polyethylene glycol monolaurate (PEGML), propylene glycol (PG), propylene glycol monolaurate (PGML), glycerol monolaurate (GML), lecithin, the 1- substituted azacycloheptan-2-ones, particularly l-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone R TM from Whitby Research Incorporated, Richmond, Na.), alcohols, and the like.
  • DMSO dimethylsulfoxide
  • DMF dimethyl formamide
  • DMA N,N-dimethylacetamide
  • Cio MSO decylmethylsulfoxide
  • PEGL poly
  • the permeation enhancer may also be a vegetable oil.
  • oils include, for example, safflower oil, cottonseed oil and corn oil.
  • Suitable anti-irritants that can be used in the context of the present invention include, for example, steroidal and non steroidal anti-inflammatory agents or other materials such as aloe vera, chamomile, alpha-bisabolol, cola nitida extract, green tea extract, tea tree oil, licoric extract, allantoin, caffeine or other xanthines, glycyrrhizic acid and its derivatives.
  • the presently known anti-irritants can be divided into water-soluble anti- irritants and water-insoluble anti-irritants.
  • compositions of the present invention in which the concentration of ammonium lactate or any other alpha-hydroxy carboxylic acid or salt thereof is higher than 10 weight percentages include one or more anti-irritants.
  • the compositions of the present invention particularly those in which the concentration of ammonium lactate or any other alpha-hydroxy carboxylic acid or salt thereof is lower than 10 weight percentages, do not include an anti-irritant, or include either water-soluble or water-insoluble anti-irritants and are therefore devoid of a combination of these two types of anti-irritants.
  • compositions of the present invention are preferably devoid of an enduring perfume composition.
  • an enduring perfume composition describes a composition that comprises one or more perfumes that provide a long lasting aesthetic benefit with a minimum amount of material. Enduring perfume compositions are substantially deposited and remain on the body throughout any rinse and/or drying steps. Representative examples of such compositions are described, for example, in U.S. Patent No. 6,086,903.
  • compositions of the present invention can comprise, in addition to ammonium lactate or any other alpha-hydroxy acid or a salt thereof, one or more other active ingredients (also referred to herein as "additional active ingredient(s)”), which are aimed at providing the composition with an additional therapeutic, cosmeceutical or cosmetic effect.
  • additional active ingredient refers to an agent, other than ammonium lactate or any other alpha-hydroxy carboxylic acid or a salt thereof, which exert a pharmacological, dermatological or any other beneficial activity.
  • Compositions according to the present invention which further comprises one or more additional active ingredients, can therefore be further efficiently used, in addition to treatment of a condition associated with dry skin and/or scalp, in the treatment of any medical, cosmetic and/or cosmeceutical condition in which applying the additional active ingredient is beneficial.
  • Preferred additional active ingredients according to the present invention include, without limitation, one or more, or any combination of an antibiotic agent, an antimicrobial agent, an anti-acne agent, an antibacterial agent, an antifungal agent, an antiviral agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflam-matory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoal agent, an anti- oxidant, a chemotherapeutic agent, an antidepressant, an anti histamine, a vitamin, a hormone and an anti-dandruff agent.
  • an antibiotic agent an antimicrobial agent, an anti-acne agent, an antibacterial agent, an antifungal agent, an antiviral agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflam-matory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoal agent, an anti- oxidant, a chemotherapeutic agent, an
  • Suitable anti-acne agents for use in this context of the present invention include, without limitation, keratolytics such as salicylic acid, sulfur, glycolic, pyruvic acid, resorcinol, and N-acetylcysteine and retinoids such as retinoic acid and its derivatives (e.g., cis and trans, esters).
  • keratolytics such as salicylic acid, sulfur, glycolic, pyruvic acid, resorcinol, and N-acetylcysteine
  • retinoids such as retinoic acid and its derivatives (e.g., cis and trans, esters).
  • Suitable antibiotics for use in this context of the present invention include, without limitation, benzoyl peroxide, octopirox, erythromycin, zinc, tetracyclin, triclosan, azelaic acid and its derivatives, phenoxy ethanol and phenoxy proponol, ethylacetate, clindamycin and meclocycline; sebostats such as flavinoids; alpha and beta hydroxy acids; and bile salts such as scymnol sulfate and its derivatives, deoxycholate and cholate.
  • non-steroidal anti-inflammatory agents include, without limitation, oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP- 14,304; salicylates, such as aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac; fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and to
  • steroidal anti-infla-mmatory drugs include, without limitation, corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha- methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flu
  • Suitable antipruritic agents include, without limitation, pharmaceutically acceptable salts of methdilazine and trimeprazine.
  • anesthetic drugs that are suitable for use in context of the present invention include pharmaceutically acceptable salts of lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine and phenol.
  • Suitable antimicrobial agents including antibacterial, antifungal, antiprotozoal and antiviral agents, for use in context of the present invention include, without limitation, beta-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, streptomycin, tobramycin, and miconazole.
  • tetracycline hydrochloride farnesol, erythromycin estolate, erythromycin stearate (salt), amikacin sulfate, doxycycline hydrochloride, chlorhexidine gluconate, chlorhexidine hydrochloride, chlortetracycline hydrochloride, oxytetracycline hydrochloride, clindamycin hydrochloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride, methacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmicin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate, mic
  • Non-limiting examples of anti-oxidants that are usable in the context of the present invention include ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox R ), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g
  • Non-limiting examples of chemotherapeutic agents usable in context of the present invention include daunorubicin, doxorubicin, idarubicin, amrubicin, pirarubicin, epirubicin, mitoxantrone, etoposide, teniposide, vinblastine, vincristine, mitomycin C, 5-FU, paclitaxel, docetaxel, actinomycin D, colchicine, topotecan, irinotecan, gemcitabine cyclosporin, verapamil, valspodor, probenecid, MK571,
  • antidepressants usable in context of the present invention include norepinephrine-reuptake inhibitors ("NRIs"), selective-serotonin- reuptake inhibitors (SSRIs), monoamine-oxidase inhibitors (MAOIs), serotonin-and- noradrenaline-reuptake inhibitors ("SNFIs), corticotropin-releasing factor (CRF) antagonists, ⁇ -adrenoreceptor antagonists, NK1 -receptor antagonists, 5-HTi A -receptor agonist, antagonists, and partial agonists and atypical antidepressants, as well as norepinephrine-reuptake inhibitors such as, but are not limited to amitriptyline, desmethylamitriptyline, clomipramine, doxepin, imipramine, imipramine, imipramine, imipramine, imipra
  • anti-dandruff ingredients usable in context of the present invention include, without limitation, zinc pyrithione, shale oil and derivatives thereof such as sulfonated shale oil, selenium sulfide, sulfur; salicylic acid, coal tar, povidone-iodine, imidazoles such as ketoconazole, dichlorophenyl imidazolodioxalan, clotrimazole, itraconazole, miconazole, climbazole, tioconazole, sulconazole, butoconazole, fluconazole, miconazolenitrite and any possible stereo isomers and derivatives thereof such as anthralin, piroctone olamine (Octopirox), selenium sulfide, and ciclopirox olamine, and mixtures thereof.
  • zinc pyrithione shale oil and derivatives thereof such as sulfonated shale oil, selenium s
  • vitamins usable in context of the present invention include vitamin A and its analogs and derivatives: retinol, retinal, retinyl palmitate, retinoic acid, tretinoin, iso-tretinoin (known collectively as retinoids), vitamin E
  • Non-limiting examples of dermatological active ingredients usable in context of the present invention include jojoba oil and aromatic oils such as methyl salicylate, wintergreen, peppermint oil, bay oil, eucalyptus oil and citrus oils, as well as ammonium phenolsulfonate, bismuth subgallate, zinc phenolsulfonate and zinc salicylate.
  • Non-limiting examples of antifungal agents include miconazole, clotrimazole, butoconazole, fenticonasole, tioconazole, terconazole, sulconazole, fluconazole, haloprogin, ketonazole, ketoconazole, oxinazole, econazole, itraconazole, terbinafine, nystatin and griseofulvin.
  • Non-limiting examples of antihistamines usable in context of the present invention include cUo hemramine, bromphenframine, dexcMo heniramine, tripolidine, clemastine, diphe-nhydramine, promethazine, piperazines, piperidines, astemizole, loratadine and terfenadine.
  • Suitable hormones for use in the context of the present invention include, for example, androgenic compounds and progestin compounds.
  • Representative examples of androgenic compounds include, without limitation, methyltestosterone, androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androsteronediol, androsteronediol-3 -acetate, androsteronediol- 17-acetate, androsteronediol 3-17-diacetate, androsteronediol- 17- benzoate, androsteronedione, androstenedione, androstenediol, dehydroepiandrosterone, sodium dehydroepiandrosterone sulfate, dromostanolone, dromostanolone propionate, ethylestrenol, fluoxymesterone, nandrolone phenpropionate, nandrolone decanoate, nandrolone furylpropionate, nandrolone cyclohexane-propionate, nand
  • progestin compounds include, without limitation, desogestrel, dydrogesterone, ethynodiol diacetate, medroxyprogesterone, levonorgestrel, medroxyprogesterone acetate, hydroxyprogesterone caproate, norethindrone, norethindrone acetate, norethynodrel, allylestrenol, 19-nortestosterone, lynoestrenol, quingestanol acetate, medrogestone, norgestrienone, dimethisterone, ethisterone, cyproterone acetate, chlormadinone acetate, megestrol acetate, norgestimate, norgestrel, desogrestrel, trimegestone, gestodene, nomegestrol acetate, progesterone, 5 ⁇ -pregnan-3 ⁇ ,20 ⁇ -diol sulf
  • compositions of the present invention may be packed or presented in any convenient way.
  • they may be packed in a tube, a bottle, or a pressurized container, using techniques well known to those skilled in the art and as set forth in reference works such as Remington's Pharmaceutical Science 15 th Ed. It is preferred that the packaging is done in such a way so as to minimize contact of the unused compositions with the environment, in order to minimize contamination of the compositions before and after the container is opened.
  • compositions of the present invention include ammonium lactate, or any other alpha-hydroxy carboxylic acid or a salt thereof, preferably in a substantial concentration
  • these compositions are useful in preventing or treating medical, cosmetic and/or cosmeceutical conditions associated with dry skin and/or scalp such as, for example, xerosis, ichthyosis, keratosis, keratoderma, pruritus, acne, dermatitis, neuro-dermatitis, dermatitis herpetiformis, actinic keratosis, hyper keratosis, inflamed keratosis, eczema, atopic eczema, melanoma, psoriasis, rosacea, urticaria, seborrheic dermatitis, skin cancer, warts, dandruffs and xeroderma pigmentosum.
  • each of the compositions described hereinabove is packaged in a packaging material and is identified in print, in or on the package, for use in the treatment or prevention of dry skin and/or scalp and/or any one or more of the conditions listed or described herein.
  • the efficacy of the compositions of the present invention in treating conditions associated with dry skin and scalp is well demonstrated in the Examples section that follows.
  • a method of treating a medical, cosmetic and/or cosmeceutical condition associated with dry skin and/or scalp is provided.
  • the method is effected by topically applying onto the affected biological surface(s) of a subject, e.g.., the dry skin and/or scalp, a pharmaceutically, cosmetically or cosmeceutically effective amount of any of the compositions of the present invention as described herein.
  • a pharmaceutically, cosmetically or cosmeceutically effective amount of any of the compositions of the present invention as described herein.
  • the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
  • topically applying describes application onto one or more biological surface(s), e.g., skin or scalp, by direct laying or spreading a composition on the surface.
  • Non-limiting examples of biological surfaces onto which the compositions of the present invention can be topically applied include the lateral aspect of forearms, the lateral aspect of legs, elbows, palms, feet, backhands, back, scalp and any other dry skin surface.
  • the compositions of the present invention are preferably topically applied between one and four times a day, more preferably twice a day (e.g., once in the morning and once in the evening).
  • the topical application of the compositions of the present invention is preferably carried out for a time period that ranges between 1 and 30 days, more preferably for a time period of about fourteen days.
  • composition that is sufficient to significantly induce a positive modification in the condition being treated, but low enough to avoid significant side effects, within the scope of sound judgment of the skilled artisan.
  • effective amount of the composition may vary with the particular skin being treated, the age and physical condition of the biological subject being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound, composition or other material employed, the particular pharmaceutically, cosmetically or cosmeceutically acceptable topical carrier utilized, and like factors within the knowledge and expertise of the skilled artisan.
  • the method according to this aspect of the present invention is preferably beneficial in treating conditions associated with dry skin and/or scalp, in cases where the compositions of the present invention further comprises additional active ingredient(s), the method can be further used for treating other conditions in which applying the additional active ingredient(s) is beneficial.
  • Such conditions include, for example, infections, fungi, allergies, aging and more.
  • a process of preparing the novel compositions described hereinabove The process generally comprises admixing the ammonium lactate or any other alpha-hydroxy carboxylic acid or salt thereof, as described hereinabove, the propellant(s) and the pharmaceutically, cosmetically or cosmeceutically acceptable carrier.
  • the process includes admixing these ingredients together with the active ingredients and the carrier.
  • the mixing technique utilized in the process of the present invention can be any one of the known techniques for formulating foamable compositions.
  • a variety of exemplary formulation techniques that are usable in the process of the present invention is described, for example, in Harry's Cosmeticology, Seventh Edition, Edited by JB Wilkinson and RJ Moore, Longmann Scientific & Technical, 1982, Chapter 13 "The Manufacture of Cosmetics" pages 757-799. Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
  • EXAMPLE 1 SKIN AND SCALP COMPOSITIONS
  • Composition 1 was prepared using conventional methods (see, for example, Harry's Cosmeticology, Seventh Edition, Edited by JB Wilkinson and RJ Moore, Longmann Scientific & Technical, 1982, Chapter 13 "The Manufacture of Cosmetics" pages 757-799).
  • the composition comprises about 10 weight percentages of a propellant, as described hereinabove.
  • Other components of the composition are listed hereinbelow.
  • GLYCERINE 5.0 % wt. ALLANTOIN 0.2 % wt. CETYL ALCOHOL 1.0 % wt. POLYSILANETM 3.0 % wt. Isopropyl myristate 4.0 % wt. MYRITOL 318TM 3.0 % wt. TWEEN 60TM 1.0 % wt. SILICON D.C.350TM 0.5 % wt. VIT.E ACETATE 0.1 % wt. MONTANON 68TM 1.5 % wt. PHE ⁇ O ⁇ IPTM 0.7 % wt. AMYLUM RICE STARCHTM 2.0 % wt.
  • test subjects were healthy volunteers, free of disease, ages 25 to 60. Each volunteer was assigned with a serial number. Ten volunteers applied the tested preparations on the forearms, as follows: A small amount of the tested preparation was applied to a clean hand. The preparation was rubbed/massaged into the forearm until it was absorbed into the skin. The preparation of this invention was applied on the left forearm. The control preparation was applied on the right forearm. The participants were asked to complete a questionnaire on their satisfaction with the preparation, once immediately after applying the preparation and a second time after half an hour.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des préparations pharmaceutiques, cosmétiques et cosméticopharmaceutiques pour applications topiques, contenant comme principe actif du lactate d'ammonium et/ou tout autre acide alpha-hydroxy carboxylique et/ou ses sels. L'invention porte également sur le procédé de fabrication de ces préparations, et sur leur utilisation pour le traitement de troubles médicaux et cosmétiques tels que ceux liés à la sécheresse de la peau ou du cuir chevelu.
PCT/IL2004/000541 2003-08-13 2004-06-17 Preparations topiques au lactate d'ammonium WO2005016360A1 (fr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US49458103P 2003-08-13 2003-08-13
US49457903P 2003-08-13 2003-08-13
US60/494,579 2003-08-13
US60/494,581 2003-08-13
US51055403P 2003-10-14 2003-10-14
US60/510,554 2003-10-14
US52727903P 2003-12-08 2003-12-08
US60/527,279 2003-12-08
US10/850,462 US20050036953A1 (en) 2003-08-13 2004-05-21 Topical compositions of ammonium lactate
US10/850,461 2004-05-21
US10/850,435 US20050042182A1 (en) 2003-08-13 2004-05-21 Topical compositions of urea
US10/850,462 2004-05-21
US10/850,435 2004-05-21
US10/850,461 US20050037040A1 (en) 2003-08-13 2004-05-21 Topical compositions of urea and ammonium lactate

Publications (1)

Publication Number Publication Date
WO2005016360A1 true WO2005016360A1 (fr) 2005-02-24

Family

ID=34199422

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IL2004/000541 WO2005016360A1 (fr) 2003-08-13 2004-06-17 Preparations topiques au lactate d'ammonium
PCT/IL2004/000542 WO2005016328A1 (fr) 2003-08-13 2004-06-17 Compositions topiques d'uree
PCT/IL2004/000543 WO2005016329A1 (fr) 2003-08-13 2004-06-17 Compositions topiques a base d'uree et de lactate d'ammonium

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/IL2004/000542 WO2005016328A1 (fr) 2003-08-13 2004-06-17 Compositions topiques d'uree
PCT/IL2004/000543 WO2005016329A1 (fr) 2003-08-13 2004-06-17 Compositions topiques a base d'uree et de lactate d'ammonium

Country Status (2)

Country Link
IL (2) IL162606A (fr)
WO (3) WO2005016360A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013110608A1 (de) * 2013-09-26 2015-03-26 Florian Lang Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948130B1 (fr) * 2005-10-24 2013-09-11 Precision Dermatology, Inc. Composition de mousse pharmaceutique topique
CA2653782A1 (fr) * 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Compositions locales
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
JP5561956B2 (ja) * 2009-04-28 2014-07-30 株式会社 資生堂 カルボキシアミド誘導体及び／またはその塩を活性成分とするｓｃｃａ−１産生抑制剤
PL2371350T3 (pl) 2010-03-04 2013-09-30 Neubourg Skin Care Gmbh & Co Kg Preparaty piankowe do leczenia chorób skóry u zwierząt
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
WO2012154122A2 (fr) * 2011-05-12 2012-11-15 Auxilium Cura Innovatio Formulation topique pour le traitement de la peau hyperkératosique
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
WO2014018874A1 (fr) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Méthode de traitement du cancer de la peau
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
CN105232357B (zh) * 2014-07-11 2020-06-26 杭州泽芙雪化妆品有限公司 一种用于治疗皮肤干燥症的保湿霜及其制备方法
CN111973478A (zh) * 2020-08-20 2020-11-24 广州博氏化妆品有限公司 一种足部护理液及其制备方法和使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439682A (en) * 1991-11-22 1995-08-08 Richardson-Vicks Inc. Combined personal cleansing and moisturizing compositions
US5750733A (en) * 1996-08-06 1998-05-12 Lever Brothers Company, Division Of Conopco, Inc. Hydroxy containing alkyl glycamides, low foaming detergent compositions comprising such and a process for their manufacture

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US5679324A (en) * 1994-07-08 1997-10-21 The Procter & Gamble Co. Aerosol foamable fragrance composition
FR2742986B1 (fr) * 1995-12-29 1998-01-30 Rhone Poulenc Chimie Compositions cosmetiques pour le cheveu ou la peau a base de copolyesters sulfones a motifs polyorganosiloxanes
US5720949A (en) * 1996-05-06 1998-02-24 Bristol-Myers Squibb Company Foamable cosmetic mask product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439682A (en) * 1991-11-22 1995-08-08 Richardson-Vicks Inc. Combined personal cleansing and moisturizing compositions
US5599549A (en) * 1991-11-22 1997-02-04 Richardson-Vicks Inc. Combined personal cleansing and moisturizing compositions
US5750733A (en) * 1996-08-06 1998-05-12 Lever Brothers Company, Division Of Conopco, Inc. Hydroxy containing alkyl glycamides, low foaming detergent compositions comprising such and a process for their manufacture

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013110608A1 (de) * 2013-09-26 2015-03-26 Florian Lang Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen

Also Published As

Publication number Publication date
IL162606A0 (en) 2005-11-20
WO2005016329A1 (fr) 2005-02-24
WO2005016328A1 (fr) 2005-02-24
IL162608A0 (en) 2005-11-20
IL162606A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
US20050042182A1 (en) Topical compositions of urea
WO2005016360A1 (fr) Preparations topiques au lactate d&#39;ammonium
US20070254953A1 (en) Topical compositions of urea and ammonium lactate
JP6653342B2 (ja) 真菌感染症の治療用の局所用オイル組成物
US5993787A (en) Composition base for topical therapeutic and cosmetic preparations
US8334413B2 (en) Topical compositions and methods for epithelial-related conditions
EP0614354B1 (fr) Emploi d&#39;acide salicylique contre l&#39;atrophie cutanee
EP2113242A1 (fr) Antioxydant destiné à une utilisation dans des préparations cosmétiques, médicamenteuses et pharmaceutiques
US9700536B2 (en) Topical formulations of tellurium-containing compounds
WO2001085156A1 (fr) Compositions dermiques ayant la coenzyme q comme principe actif
US20110082118A1 (en) Onychomycosis Treatment Delivery System
US5045559A (en) Treatment of skin disorders
AU2013343232A1 (en) Dermal compositions containing unnatural hygroscopic amino acids
EP1765376B1 (fr) Compositions topiques et utilisation de celles-ci pour lutter contre des maladies epitheliales
US20050123575A1 (en) Spreadable compositions for topical use, an improved process of making same and methods of using same
US20050036953A1 (en) Topical compositions of ammonium lactate
US8080237B2 (en) Use of tellurium compounds for protection from ultra-violet radiation
GB2456528A (en) Transition metal pyrrolidone carboxylic acids (PCA) as antioxidants in cosmetic preparations
JPS63297309A (ja) 皮膚外用剤
CA2203920A1 (fr) Compositions deodorantes, antimicrobiennes et conservatrices et leurs procedes d&#39;utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载